We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Risk management in the treatment of type 2 diabetes with pioglitazone.
- Authors
Derosa, Giuseppe; Salvadeo, Sibilla A. T.
- Abstract
Introduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Pioglitazone is an insulin-sensitizing agent available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of pioglitazone in achieving metabolic control and reducing cardiovascular morbidity and mortality. Aim: The purpose of this article is to review the effectiveness and tolerability of pioglitazone in the prevention and management of atherosclerosis in patients with type 2 diabetes. Evidence review: We reviewed the main monotherapy and comparative studies of pioglitazone, and particularly the recent evidence in the field of atherosclerosis and cardiovascular prevention. Place in therapy: The current evidence shows that pioglitazone is an effective option in the treatment of type 2 diabetes. More studies are needed to establish a role for pioglitazone in atherosclerosis prevention beyond glycemic control.
- Publication
Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2009, Vol 2, p51
- ISSN
1178-7007
- Publication type
Article